NDC-11 (Package) (Descending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
62756-0093-40 | 62756-0093 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 7, 2012 | Jan. 31, 2017 | No Longer Used | |
62756-0073-60 | 62756-0073 | gemcitabine | INFUGEM | 10.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 1, 2018 | July 31, 2023 | No Longer Used |
62756-0023-43 | 62756-0023 | Topotecan Hydrochloride | Topotecan hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sept. 2, 2015 | Sept. 30, 2015 | No Longer Used |
62756-0023-40 | 62756-0023 | Topotecan Hydrochloride | Topotecan hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sept. 2, 2015 | Sept. 30, 2015 | No Longer Used |
62756-0008-60 | 62756-0008 | gemcitabine | INFUGEM | 10.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 1, 2018 | July 31, 2023 | No Longer Used |
62584-0827-21 | 62584-0827 | Cyclosporine | Cyclosporine | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Dec. 11, 2009 | Sept. 30, 2011 | No Longer Used | |
62584-0827-11 | 62584-0827 | Cyclosporine | Cyclosporine | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Dec. 11, 2009 | Sept. 30, 2011 | No Longer Used | |
62559-0931-01 | 62559-0931 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | June 22, 2020 | Aug. 31, 2023 | No Longer Used |
62559-0930-01 | 62559-0930 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | June 22, 2020 | March 31, 2023 | No Longer Used |
62559-0925-51 | 62559-0925 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Oct. 31, 2022 | No Longer Used |
62559-0924-51 | 62559-0924 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Feb. 28, 2023 | No Longer Used |
62559-0924-14 | 62559-0924 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Feb. 28, 2023 | No Longer Used |
62559-0923-51 | 62559-0923 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Feb. 28, 2023 | No Longer Used |
62559-0923-14 | 62559-0923 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Feb. 28, 2023 | No Longer Used |
62559-0922-51 | 62559-0922 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Feb. 28, 2023 | No Longer Used |
62559-0922-14 | 62559-0922 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Feb. 28, 2023 | No Longer Used |
62559-0921-51 | 62559-0921 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Feb. 28, 2023 | No Longer Used |
62559-0921-14 | 62559-0921 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | Feb. 28, 2023 | No Longer Used |
62559-0920-51 | 62559-0920 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | In Use | |
62559-0920-14 | 62559-0920 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | In Use | |
62559-0890-30 | 62559-0890 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Oct. 26, 2020 | In Use | |
62559-0680-30 | 62559-0680 | Bicalutamide | CASODEX | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | June 26, 2018 | In Use | |
62559-0670-30 | 62559-0670 | Anastrozole | ARIMIDEX | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 26, 2018 | In Use | ||
62559-0540-55 | 62559-0540 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 250.0 mg/mL | Hormonal Therapy | Progestin | Intramuscular | June 3, 2016 | June 3, 2016 | No Longer Used | |
62559-0540-15 | 62559-0540 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 250.0 mg/mL | Hormonal Therapy | Progestin | Intramuscular | June 3, 2016 | July 31, 2018 | No Longer Used | |
62559-0173-31 | 62559-0173 | Nilutamide | Nilutamide | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 18, 2016 | In Use | |
62484-0020-02 | 62484-0020 | Purixan | Purixan | 20.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 28, 2014 | In Use | |
62484-0020-01 | 62484-0020 | Purixan | Purixan | 20.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 28, 2014 | In Use | |
62332-0779-31 | 62332-0779 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 18, 2023 | In Use | |
62332-0751-50 | 62332-0751 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 3, 2023 | In Use | |
62332-0730-36 | 62332-0730 | METHOTREXATE | METHOTREXATE | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | June 4, 2024 | In Use | |
62332-0730-31 | 62332-0730 | METHOTREXATE | METHOTREXATE | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | June 4, 2024 | In Use | |
62332-0678-16 | 62332-0678 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 28, 2023 | In Use | |
62332-0678-10 | 62332-0678 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 28, 2023 | In Use | |
62332-0678-02 | 62332-0678 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 28, 2023 | In Use | |
62332-0659-02 | 62332-0659 | Carmustine | Carmustine | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Oct. 20, 2023 | In Use | ||
62332-0650-10 | 62332-0650 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Dec. 22, 2022 | In Use | ||
62332-0650-05 | 62332-0650 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Dec. 22, 2022 | In Use | ||
62332-0622-50 | 62332-0622 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
62332-0621-17 | 62332-0621 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
62332-0620-05 | 62332-0620 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
62332-0619-31 | 62332-0619 | Cyclophosphamide | Cyclophosphamide | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Nov. 23, 2022 | In Use | |
62332-0618-31 | 62332-0618 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Nov. 23, 2022 | In Use | |
62332-0567-90 | 62332-0567 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0567-30 | 62332-0567 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0566-90 | 62332-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0566-30 | 62332-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0565-90 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0565-30 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62175-0888-32 | 62175-0888 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 3, 2011 | June 16, 2017 | No Longer Used |
Found 10,000 results in 6 milliseconds — Export these results